CA
NZ
UK
AU
IND
US
…
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -112.03M | -100.78M | -79.21M | -43.76M | -81.71M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -108.91M | -100.74M | -79.19M | -43.76M | -81.71M |
| Selling general administrative | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M |
| Gross profit | 115.16M | -100.89M | -80.15M | - | 0.00M |
| Reconciled depreciation | 0.04M | 0.04M | 0.02M | - | - |
| Ebit | -115.16M | -100.93M | -80.17M | -43.76M | -13.78M |
| Ebitda | -111.29M | -100.89M | -80.15M | -45.65M | -81.71M |
| Depreciation and amortization | 3.86M | 0.04M | 0.02M | - | -67.94M |
| Non operating income net other | 3.93M | 0.09M | 0.95M | - | - |
| Operating income | -115.16M | -100.89M | -80.15M | -45.65M | -13.78M |
| Other operating expenses | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M |
| Interest expense | 0.74M | 0.04M | 0.00M | 0.00M | 0.00M |
| Interest income | - | - | - | - | 62.15M |
| Net interest income | -0.74M | - | - | - | - |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | -3.12M | -0.04M | -0.02M | -1.90M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M |
| Cost of revenue | -115.16M | 100.89M | 80.15M | - | 0.00M |
| Total other income expense net | 3.12M | 0.11M | 0.95M | 1.90M | -67.94M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -111.97M | -100.80M | -79.21M | -43.76M | -81.71M |
| Net income applicable to common shares | -112.03M | -100.78M | -79.21M | -43.76M | -82.23M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 580.27M | 356.57M | 195.55M | 273.34M | 138.12M |
| Other current assets | 9.95M | 3.72M | 5.32M | 2.96M | 1.65M |
| Total liab | 44.97M | 30.01M | 26.44M | 14.63M | 9.39M |
| Total stockholder equity | 535.31M | 326.56M | 169.11M | 258.71M | 128.73M |
| Deferred long term liab | - | 0.30M | - | 0.05M | - |
| Other current liab | 11.83M | 10.79M | 18.22M | 9.39M | 8.42M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -574.10M | -422.34M | -310.30M | -209.53M | -130.32M |
| Other liab | - | 0.30M | - | - | 0.02M |
| Other assets | 0.00M | 0.11M | 0.42M | 0.20M | 0.07M |
| Cash | 234.21M | 249.77M | 150.48M | 187.24M | 136.40M |
| Total current liabilities | 19.13M | 19.08M | 25.13M | 13.11M | 9.37M |
| Net debt | -208.16M | -238.83M | -148.97M | -185.43M | -136.40M |
| Short term debt | 0.26M | 0.33M | 0.20M | 0.29M | - |
| Short long term debt total | 26.04M | 10.95M | 1.52M | 1.81M | - |
| Other stockholder equity | 1109.13M | 748.86M | 479.44M | 468.24M | 120.93M |
| Property plant equipment | - | 0.05M | 0.09M | 1.79M | - |
| Total current assets | 559.96M | 355.17M | 193.58M | 271.35M | 138.05M |
| Long term investments | 19.28M | - | - | - | - |
| Net tangible assets | - | 326.56M | 169.11M | 258.71M | 128.73M |
| Short term investments | 315.80M | 101.68M | 37.77M | 81.14M | 71.61M |
| Net receivables | - | - | 0.42M | 0.20M | - |
| Long term debt | 24.96M | 9.54M | - | - | - |
| Accounts payable | 7.04M | 7.97M | 6.71M | 3.43M | 0.95M |
| Accumulated other comprehensive income | 0.27M | 0.04M | -0.03M | -0.00M | -0.01M |
| Common stock total equity | - | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings total equity | - | -422.34M | -310.30M | -209.53M | - |
| Non currrent assets other | -0.00M | 0.11M | 0.42M | 0.20M | 0.07M |
| Non current assets total | 20.31M | 1.40M | 1.97M | 1.99M | 0.07M |
| Capital lease obligations | 1.34M | 1.40M | 1.52M | 1.81M | - |
| Long term debt total | - | 9.54M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -63.83M | 42.28M | -9.76M | -71.51M | -71.51M |
| Change to liabilities | -6.37M | 12.01M | 2.48M | -0.43M | 1.31M |
| Total cashflows from investing activities | -63.83M | 42.28M | -9.76M | -71.51M | -5.00M |
| Net borrowings | 9.61M | 10.00M | 10.00M | 10.00M | 0.00M |
| Total cash from financing activities | 255.63M | 0.60M | 203.11M | 95.99M | 85.01M |
| Change to operating activities | -5.43M | 6.45M | -0.40M | 6.89M | -0.25M |
| Net income | -112.03M | -100.78M | -79.21M | -43.76M | -81.71M |
| Change in cash | 99.29M | -36.80M | 122.54M | -11.15M | 75.38M |
| Begin period cash flow | 150.59M | 187.39M | 64.85M | 76.00M | 0.62M |
| End period cash flow | 249.88M | 150.59M | 187.39M | 64.85M | 76.00M |
| Total cash from operating activities | -92.52M | -79.68M | -70.80M | -35.63M | -4.62M |
| Issuance of capital stock | 241.20M | 0.00M | 202.55M | 95.45M | 85.50M |
| Depreciation | 0.04M | 0.04M | 0.02M | -0.10M | 0.02M |
| Other cashflows from investing activities | - | - | - | -71.51M | -5.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | - | - | - | - | 0.00M |
| Sale purchase of stock | 0.28M | 0.37M | 0.20M | 0.09M | 85.51M |
| Other cashflows from financing activities | 14.55M | 0.23M | 0.35M | 0.45M | 85.01M |
| Change to netincome | 23.52M | 10.06M | 6.30M | 1.67M | 76.03M |
| Capital expenditures | 0.00M | 0.00M | 0.15M | 0.15M | 5.00M |
| Cash flows other operating | 2.12M | -2.08M | -1.32M | - | - |
| Cash and cash equivalents changes | 99.29M | -36.80M | 122.54M | - | - |
| Change in working capital | -4.46M | 9.73M | 2.08M | 6.46M | 1.06M |
| Stock based compensation | 23.24M | 10.05M | 6.02M | 1.77M | 0.12M |
| Other non cash items | 0.69M | 0.20M | 0.20M | -0.10M | 75.91M |
| Free cash flow | -92.52M | -79.68M | -70.95M | -35.63M | -9.62M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
650 487 6488
60
| Name | Title | Year Born |
|---|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | Pres, CEO & Director | 1967 |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Exec. VP, COO & Sec. | 1970 |
| Dr. Timothy Rolph | Co-Founder & Chief Scientific Officer | 1954 |
| Mr. William R. White J.D. | Exec. VP, CFO, Treasurer & Head of Corp. Devel. | 1973 |
| Ms. Catriona Yale | Exec. VP & Chief Devel. Officer | 1972 |
| Mr. John J. Schembri | VP of Fin. & Controller | 1962 |
| Dr. Andrew Cheng M.D., Ph.D. | President, CEO & Director | 1967 |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive VP, COO & Secretary | 1970 |
| Mr. William R. White J.D. | Executive VP, CFO, Treasurer & Head of Corporate Development | 1974 |
| Ms. Catriona Yale | Executive VP & Chief Development Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...